TSS
ALNY icon

Two Sigma Securities’s Alnylam Pharmaceuticals ALNY Stock Holding History

Two Sigma Securities’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,400
Closed -$935K – 1637
2024
Q3 		$935K Sell
3,400
-20,400
-86% -$5.31M 0.02% 914
2024
Q2 		$5.78M Buy
23,800
+18,000
+310% +$2.84M 0.07% 316
2024
Q1 		$867K Sell
5,800
-8,400
-59% -$1.4M 0.01% 1222
2023
Q4 		$2.72M Buy
14,200
+11,100
+358% +$1.89M 0.03% 575
2023
Q3 		$549K Buy
+3,100
New +$591K 0.01% 1464
2022
Q2 		– Sell
-2,000
Closed -$327K – 2183
2022
Q1 		$327K Buy
+2,000
New +$305K 0.01% 1332
2020
Q2 		– Sell
-4,700
Closed -$512K – 1350
2020
Q1 		$512K Buy
4,700
+900
+24% +$104K 0.01% 614
2019
Q4 		$438K Buy
+3,800
New +$379K ﹤0.01% 1531
2018
Q3 		– Sell
-2,400
Closed -$236K – 2543
2018
Q2 		$236K Sell
2,400
-10,800
-82% -$1.07M ﹤0.01% 2233
2018
Q1 		$1.57M Buy
+13,200
New +$1.7M 0.01% 1018

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Securities's ALNY Position: Q2 2026 in Review

Two Sigma Securities opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 5,585 shares worth $1.68M. The stake represents 0.15% of the portfolio and ranks #143 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in ALNY as recently as Q3 2025.

Two Sigma Securities first reported a position in ALNY in Q2 2017 and has held it in 17 quarters since. The position peaked at $13.2M in Q2 2024. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Two Sigma Securities held 5,585 shares of Alnylam Pharmaceuticals worth $1.68M as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Two Sigma Securities position in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.15% of Two Sigma Securities's portfolio in Q2 2026, its #143 holding.
  • Two Sigma Securities first reported a position in Alnylam Pharmaceuticals in Q2 2017 and has held it in 17 quarters since.
  • Two Sigma Securities's Alnylam Pharmaceuticals position peaked at $13.2M in Q2 2024.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.